anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention belongs to medicinal, sanitary, food and chemical industries, which mainly relates to a morinda officinalis element A, a preparation method and the application thereof. The morinda officinalis of traditional Chinese medicine is a fleshy root of rubiaceae plant morinda officinalis (Morinda officinalis How) which is the usual traditional Chinese medicine for tonifying the kidneys all the time. Proved by modern research, the morinda officinalis has the kidney tonifying effects of promoting adrenocortical hormone, enhancing the hypothalamus, the hypophysis and sex gland axes, enhancing the thyroid, promoting breeding, promoting corticosterone secretion, enhancing drosophila character activity and eclosion rate, etc. The present invention provides a method for preparing morinda officinalis element A, which comprises: the morinda officinalis is extracted by a solvent method; after concentration, alcohol deposition, column chromatography separation and recrystallization, the morinda officinalis element A is obtained. The new compound-morinda officinalis element A which has biological activity is separated from the morindae officinalis of the traditional Chinese medicine, and can be applied to senile dementia, the treatment and the prevention of other senile diseases and the treatment and the prevention of the diseases, such as teenager hypophrenia, etc. High-grade food additives, health foods, etc. are added into the morinda officinalis element A, and thus, the application values and the economic benefit of the morindae officinalis of the traditional Chinese medicine are obviously enhanced.
Hereditary liver diseases are rare conditions characterized by a wide variety of types and very low incidence rate for each one. Their clinical manifestations are diverse, and diagnosis often requires specialized testing, posing a high likelihood of missed or misdiagnosis. Systemic learning the basic knowledge and classification of hereditary liver diseases, as well as an understanding of the clinical features, laboratory findings, imaging, and pathological features of the relatively common hereditary liver diseases in adults, such as Wilson's disease, hemochromatosis, and alpha-1 antitrypsin deficiency, is essential. Targeted genetic testing can aid in the timely identification and correct diagnosis of these diseases. Once the etiology is revealed, appropriate treatment can often improve the clinical outcomes and quality of life. Cell therapy and gene therapy represent future directions and may offer the chance of cure for certain conditions. Currently, for patients who have progressed to end-stage liver disease, liver transplantation remains the ultimate treatment option and mostly yield excellent long-term prognosis if the indication and timing are appropriate.
A stent-graft planning system is a web-based system that assists a physician in selecting and ordering the right stent-graft online in real-time. The stent-graft planning system provides a physician with a two-dimensional (2D) graphic model reflecting the individual vessel anatomy, e.g., aneurismal anatomy, and the selected stent graft in that anatomy. By comparing the graphic model with the image of the patient's vessels, the physician can note any dimensions that are inconsistent with the graphic image and problems with the stent-graft placement. Each collected measurement is validated and the physician is warned if the measurement suggests a problem. The stent-graft system automatically generates the most suitable stent graft for an individual patient. After reviewing the selected stent graft in the 2D model, the stent graft can be ordered online.
OBJECTIVE: To compare the effectiveness of general exercises with specific exercises for pain and functional disability of individuals with chronic nonspecific neck pain.
METHOD: This systematic review of clinical trials searched MEDLINE, CINAHL, Embase, CENTRAL, and PEDro databases with no date or language restriction. Methodological quality of evidence were assessed using the PEDro scale and GRADE, respectively. Pain and functional disability were the primary outcomes.
RESULTS: This review included 14 articles from 12 studies, from which nine were included in meta-analyses. Data were from 926 individuals with chronic nonspecific neck pain, comparing specific exercises with mind-body and aerobic exercises (general exercises). Pain intensity was not different between aerobic and specific exercises, with a mean difference (MD) of 0.95 points (95% CI -1.62 to 3.51) in the medium-term and 0.32 points (95% CI -1.05 to 1.68) in the long-term. Mind-body exercises were not better than specific exercises for pain intensity in medium- (MD 0.54 points; 95% CI 0.00 to 1.08) or long-term (MD 0.06 points; 95% CI -0.59 to 0.46). Also, mind-body exercises did not improve functional disability compared with specific exercises in medium- or long-term (MD 0.01 points; 95% CI -0.25 to 0.27). The quality of evidence among studies ranged from very low to low across all comparisons.
CONCLUSION: General exercises are not superior to specific exercises for pain and functional disability in individuals with chronic nonspecific neck pain.
BACKGROUND: Infections frequently complicate hospital admission among patients with cirrhosis and are associated with adverse outcomes. In specific settings, administration of prophylactic antibiotics has been shown to improve outcomes. In this pilot study, we aimed to assess the feasibility of a randomized study of whether prophylactic ceftriaxone (CTX), administered to hospitalized patients with advanced cirrhosis (Model for End-Stage Liver Disease-Sodium ≥ 18) without known infection, could reduce the incidence of infection. We also sought to determine whether we could identify patients most likely to benefit through the use of clinical and laboratory parameters.
METHODS: Hospitalized patients with cirrhosis, with Model for End-Stage Liver Disease-Sodium ≥ 18 and no known infection after evaluation, were randomly assigned in a double-blinded fashion to receive either CTX 1 gr/day or placebo for up to 7 days. Subjects were monitored for incident infection and other outcomes of interest, including adverse reactions such as the development of C. difficile infection. Biomarkers of interest, including C-reactive protein and procalcitonin, were measured before initiation of treatment.
RESULTS: Thirty subjects were enrolled and received CTX or placebo (15 subjects each) per protocol. There were no observed statistically significant differences between groups in incidence of infection, mortality, length of stay, or key laboratory parameters, including C-reactive protein and procalcitonin. Adverse events related to treatment were rare and clinically of minor significance.
CONCLUSIONS: Overall, enrollment of subjects proved feasible, and results from this pilot study, while inadequate for confirmation of the potential efficacy of CTX, provide evidence of study feasibility for future, more definitive clinical trials.
Human Experience

In clinical trials of citalopram, there were reports of citalopram overdose, including overdoses of up to 2000 mg, with no associ¬ated fatalities. During the postmarketing evaluation of citalopram, Citalopram hydrobromide overdoses, including overdoses of up to 6000 mg, have been reported. As with other SSRI’s, a fatal outcome in a patient who has taken an overdose of citalopram has been rarely reported.

Symptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizzi¬ness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc pro¬longation, nodal rhythm, ventricular arrhythmia, very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose.

Management of Overdose

Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of acti¬vated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large vol¬ume of distribution of citalopram, forced diuresis, dialysis, hemop¬erfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for Citalopram hydrobromide.

In managing over dosage, consider the possibility of multiple-drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose.
Receives both Experimental and Generic AAC systems to communicate. Each participant will receive both devices, with Experimental AAC presented first (Day 1) and Generic AAC presented second (Day 2; reference).
BACKGROUND: In the past decade, there have been substantial advances in our understanding of the pathobiology of pediatric acute kidney injury (AKI). In particular, animal models and studies focused on the relationship between kidney development, nephron number, and kidney health have identified a number of heterogeneous pathophysiologies underlying AKI. Despite this progress, gaps remain in our understanding of the pathobiology of pediatric AKI.
METHODS: During the 26th Acute Disease Quality Initiative (ADQI) Consensus conference, a multidisciplinary group of experts discussed the evidence and used a modified Delphi process to achieve consensus on recommendations for opportunities to advance translational research in pediatric AKI. The current state of research understanding as well as gaps and opportunities for advancement in research was discussed, and recommendations were summarized.
RESULTS: Consensus was reached that to improve translational pediatric AKI advancements, diverse teams spanning pre-clinical to epidemiological scientists must work in concert together and that results must be shared with the community we serve with patient involvement. Public and private research support and meaningful partnerships with adult research efforts are required. Particular focus is warranted to investigate the pediatric nuances of AKI, including the effect of development as a biological variable on AKI incidence, severity, and outcomes.
CONCLUSIONS: Although AKI is common and associated with significant morbidity, the biologic basis of the disease spectrum throughout varying nephron developmental stages remains poorly understood. An incomplete understanding of factors contributing to kidney health, the diverse pathobiologies underlying AKI in children, and the historically siloed approach to research limit advances in the field. The recommendations outlined herein identify gaps and outline a strategic approach to advance the field of pediatric AKI via multidisciplinary translational research.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Ciprofloxacin Tablets USP for a condition for which it is not prescribed. Do not give Ciprofloxacin Tablets USP to other people, even if they have the same symptoms that you have. It may harm them. 

This Medication Guide summarizes the most important information about Ciprofloxacin Tablets USP. If you would like more information about CIPRO, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Ciprofloxacin Tablets USP that is written for healthcare professionals.

For more information 1-(866)-562-4597
The invention relates to a traditional Chinese medicine for treating acute myelitis. The traditional Chinese medicine is prepared from, by weight, 18 parts of Radix Ranunculi Ternati, 12 parts of Airpotato Yam Rhizome, 10 parts of Rhizoma Curcumae, 15 parts of Herb of Dracocephalum heterophyllum Benth., 10 parts of Herb of Pilosella-leaved Drymoglossum, 30 parts of Fruit of Emblic Leafflower, 12 parts of Artemisia capillaries, 12 parts of Wrightia. tomentosa Roem. & Sch. and 12 parts of Radix Curcumae Aromaticae. Clinic experiments prove that the acute myelitis can be safely and effectively treated by using the traditional Chinese medicine.
Distinct subsets of T lymphocytes express CX3CR1 under inflammatory conditions, but little is known about CX3CR1+CD4+ T cells during type 2 inflammation in helminth infections. In this study, we used a fate-mapping mouse model to characterize CX3CR1+CD4+ T cells during both acute Nippostrongylus brasiliensis and chronic Schistosoma mansoni murine models of helminth infections, revealing CX3CR1+CD4+ T cells to be an activated tissue-homing subset with varying capacity for cytokine production. Tracking these cells over time revealed that maintenance of CX3CR1 itself along with a TH2 phenotype conferred a survival advantage in the inflamed tissue. Single-cell RNA sequencing analysis of fate-mapped CX3CR1+CD4+ T cells from both the peripheral tissue and the spleen revealed a considerable level of diversity and identified a distinct population of BCL6+TCF-1+PD1+CD4+ T cells in the spleen during helminth infections. Conditional deletion of BCL6 in CX3CR1+ cells resulted in fewer CX3CR1+CD4+ T cells during infection, indicating a role in sustaining CD4+ T cell responses to helminth infections. Overall, our studies revealed the behavior and heterogeneity of CX3CR1+CD4+ T cells during type 2 inflammation in helminth infections and identified BCL6 to be important in their maintenance.
The present invention relates to a platelet aggregation inhibitor containing a Schizandra chinensis seed extract as an active ingredient. More specifically, the present invention relates to a strong platelet aggregation inhibitor using a Schizandra chinensis seed ethanol extract and a lipid soluble hexene fragment thereof as active ingredients. The Schizandra chinensis seed extract as an active ingredient of a platelet aggregation inhibitor of the present invention shows a strong anti-aggregation activity by an effect in inhibiting the aggregation of platelets which initiates thrombogenesis. The extract has excellent thermal stability, and an activity of inhibiting platelet aggregation is not severely reduced even in acidic conditions of pH 2 and in plasma. The extract is processed into various forms such as liquids, powder, pills, and tablets to be always dosed. Accordingly, the present invention is very useful in the pharmaceutical industries and the food industries.
BACKGROUND: Therapy-related acute myeloid leukemia (t-AML) is considered high risk as it related to prior exposure to cytotoxic chemotherapy agents for solid tumors or hematologic malignancies. Compared with de novo AML, t-AML is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. Many efforts have been devoted to improving the overall but with limited success, and novel strategy is thus highly needed.
CASE DESCRIPTION: We reported one patient with refractory/relapsed t-AML was successfully treated with Palbociclib combined with Venetoclax and Azacytidine (AZA). In this case, a 47-year-old patient with t-AML recurred during Venetoclax in combination with AZA therapy. However, the patient achieved morphological, immunophenotypic and molecular complete remission again after Palbociclib combined with Venetoclax and AZA.
CONCLUSIONS: Although only one successful case is presented here, three-drug combination regimens should be considered as another treatment option for t-AML in the future.
1. A pharmaceutical composition, substantially free of ethanol and containing less than 0.005% ethylenediaminetetraacetic acid, comprising lamivudine or a pharmaceutically acceptable derivative thereof, and a preservative system, wherein the preservative system further comprises parabens, said composition having a pH greater than 5.5. 2. A pharmaceutical composition comprising lamivudine, said composition being substantially free of ethanol and contianing less than 0.005% ethylenediaminetetraacetic acid and exhibiting antimicrobial preservative efficacy, further comprising parabens, said composition having a pH greater than 5.5. 3. A pharmaceutical composition, substantially free of ethanol and containing less than 0.005% ethylenediaminetetraacetic acid, comprising lamivudine or a pharmaceutically acceptable derivative thereof, methyl paraben, and propyl paraben, said composition having a pH greater than 5.5. 4. A pharmaceutical composition according to any of Claims 1-3 wherein the concentration of methyl paraben is 0.96 mg/mL to 2 mg/mL and the concentration of propyl paraben is 0.1 mg/mL to 0.2 mg/mL. 5. A pharmaceutical composition according to any of Claims 1-4 wherein the pH is in the range 5.56-7.4. 6. A pharmaceutical composition according to Claim 5 wherein the pH is 6.0. 7. A pharmaceutical composition as claimed in any preceding claim wherein the amount of lamivudine is in the range of 0.1-100 mg/mL. 8. A pharmaceutical composition as claimed in claim 7 wherein the amount of lamivudine is in the range of 5-20 mg/ml. 9. A pharmaceutical composition as claimed in any preceding claim further comprising a second therapeutic agent. 10. A pharmaceutical composition as claimed in any preceding claim for oral administration. 11. A method of treatment of viral infections by administering a pharmaceutically safe and effective amount of a pharmaceutical composition according to Claims 1-10. 12. Use of lamivudine or a pharmaceutically acceptable derivative thereof, for the manufacture of a pharmaceutical composition according to any of Claims 1-10, for use in the treatment or prophylaxis of viral infections. 13. Use of lamivudine as claimed in Claim 12, for the treatment or prophylaxis of HIV. 14. Use of lamivudine as claimed in Claim 12, for the treatment or prophylaxis of HBV. 15. A process for the preparation of a pharmaceutical composition as claimed in any one of Claims 1 to 10 which comprises the step of bringing into association lamivudine or a pharmaceutically acceptable derivative thereof with a carrier.
The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including CYMBALTA, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). 

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome. 

The concomitant use of CYMBALTA with MAOIs intended to treat psychiatric disorders is contraindicated. CYMBALTA should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking CYMBALTA. CYMBALTA should be discontinued before initiating treatment with the MAOI [see Dosage and Administration (2.8, 2.9), and Contraindications (4)].

If concomitant use of CYMBALTA with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. Treatment with CYMBALTA and any concomitant serotonergic agents, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
Based on CDC's guidance on PrEP as well as results of randomized controlled trials, the U.S. Food and Drug Administration (FDA) approved this daily medication (comprised of one pill) to reduce the risk of sexually acquired HIV in adults at high risk. Other medical practices to avoid transmission within this population include assisted reproductive technologies such as sperm washing (or donated sperm) coupled with in vitro fertilization, intracytoplasmic sperm injection (an in vitro procedure where a single sperm is injected directly into an egg), and intrauterine insemination (placing the sperm directly into the uterus). However, these methods are costly and often regionally scarce. PrEP is more accessible and a less expensive option for couples. When used consistently and as prescribed, PrEP has shown to significantly reduce the risk of HIV infection among adult men and women. However, risk reduction counseling and clinical monitoring are necessary for its effective implementation. Therefore, beyond efficacy trials, it is important to conduct additional studies of pre-exposure prophylaxis to observe what factors make PrEP feasible and acceptable to couples, as well as identify other factors that impact level of adherence. The study will take place in four U.S. cities: Boston, Baltimore, Philadelphia, and San Francisco and will involve couples who have chosen to begin PrEP for conception as part of their clinical care after receiving preconception counseling and reviewing their options with their health care provider.
Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
Post-COVID-19 patients are individuals who have recovered from the acute phase of COVID-19 but continue to experience lingering symptoms and health challenges for weeks or even months after their initial infection. These individuals are often referred to as "long haulers" or "post-acute sequelae of SARS-CoV-2 infection" (PASC) patients. The symptoms experienced by post-COVID-19 patients can vary widely and may include fatigue, shortness of breath, chest pain, joint pain, cognitive difficulties, and more. Medical professionals and researchers are working to better understand and address these conditions, providing supportive care and rehabilitation to help these patients regain their health and well-being.